Cargando…

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center

BACKGROUND: Dalbavancin is a novel long-acting lipoglycopeptide with increasing utilization for management of bone and joint infections as a two-dose regimen. The purpose of this study is to describe the patient characteristics, evaluate clinical outcomes, and calculate inpatient hospital days saved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napoli, Emma, Badwal, Jasmin K, Kirkpatrick, Emily R, Pinilla, Ruth Serrano, Wang, Chen-Pin, Javeri, Heta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777104/ http://dx.doi.org/10.1093/ofid/ofaa439.510

Ejemplares similares

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

1402. NTM Infections; A Rising Global Health Problem/Clinical Characteristics and Outcomes of Patients with Non-Tuberculous Mycobacterial Infections at Two Tertiary Academic Medical Centers
por: Nawwar, Abdelhameed, et al.
Publicado: (2021)

608. Impact of Implementing Pharmacist Review and Monitoring of Outpatient Parenteral Antimicrobial Therapy
por: Kirkpatrick, Emily R, et al.
Publicado: (2020)

161. Flucytosine Utilization and Dosing Practices at an Academic Medical Center
por: Miller, Molly M, et al.
Publicado: (2021)

1178. The Dalba Diary: A Retrospective Review of Dalbavancin Use, Clinical Outcomes, and Treatment Adherence Challenges at an Academic Medical Center
por: Black, Cassandra E, et al.
Publicado: (2023)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

323. Outpatient Initiation and Successful Completion of Intravenous Antibiotic Therapy at Home for Eligible Patients: A Quality Improvement Project
por: Henry Cedeno, Mark, et al.
Publicado: (2023)

314: The COVID-19 pandemic and trends in anxiety and depressive symptoms in adolescents with cystic fibrosis and their caregivers
por: Szentpetery, S., et al.
Publicado: (2021)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

802. Use of N-Acetylcysteine for Prevention and Treatment of Isoniazid Induced Liver Injury During Treatment of Mycobacterial Infections
por: Diaz, Heidi Torres, et al.
Publicado: (2018)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
por: Simonetti, Oriana, et al.
Publicado: (2021)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

1247. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients
por: Diaz, Julia Garcia, et al.
Publicado: (2020)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

589. Use of Dalbavancin in Facilitating Discharge of High Risk Patients in Low Resource Settings
por: Milgrom, Alexander
Publicado: (2020)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

234. Dalbavancin versus Outpatient Parenteral Antimicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

Financial Value of Plastic Surgeons to an Academic Medical Center as Operative Consultants
por: Vartanian, Emma D., et al.
Publicado: (2019)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
por: Greckel, Meagan N, et al.
Publicado: (2022)

Barriers to the implementation of checklists in the ICU: a survey on the perceptions of 314 Brazilian critical care nurses and physicians
por: Salluh, J, et al.
Publicado: (2015)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Dalbavancin in clinical practice in Spain: a 2 year retrospective study
por: Morata, Laura, et al.
Publicado: (2022)

971. Unmasking the Undetectable: Identifying and Troubleshooting a Series of Falsely Elevated HIV Viral Load Results in a Group of Patients in a Community Clinic in San Antonio, Texas
por: Pinilla, Ruth Serrano, et al.
Publicado: (2020)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population
por: Murray, E Yancey, et al.
Publicado: (2020)

Health Tract No. 314: Marriage Maxims
Publicado: (1868)

Cannot write session to /tmp/vufind_sessions/sess_4t3g71vl98agf0mbl3rf2bb1ve